Why Bain Capital Is Selling Shares of This Biotech Stock Now

Core Insights - Pharvaris N.V. is focused on developing innovative oral therapies for rare diseases, particularly hereditary angioedema (HAE) [3][2] - The company operates a clinical-stage biopharmaceutical model, investing in research and development to advance its pipeline through regulatory milestones for future commercialization [1][3] Company Overview - Pharvaris N.V. develops small molecule therapies for HAE, including PHA121, PHVS416, and PHVS719 [2] - The company leverages proprietary small molecule technology to address significant unmet medical needs in the rare disease space [3] Financial Performance - As of November 14, 2025, shares of Pharvaris N.V. were priced at $23.55, reflecting a 14.6% increase over the past year, outperforming the S&P 500 by 5.01 percentage points [4] - Bain Capital Life Sciences Investors, LLC sold 122,106 shares of Pharvaris N.V. during the third quarter, reducing its position value by $21.23 million, with remaining shares valued at $79.37 million [5][6] Market Context - Pharvaris stock has increased over 50% in the last six months, nearing its 52-week high of $26.33 [8] - Despite the sale of shares by Bain Capital, the total value of its Pharvaris stock increased from approximately $58 million at the end of Q2 to $79 million at the end of Q3 [9]